- Home
- LH vs EXAS Comparison
LH vs EXAS Comparison
Compare LH & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | EXAS |
|---|---|---|
| Founded | 1971 | 1995 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9B | 19.6B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LH | EXAS |
|---|---|---|
| Price | $282.67 | $103.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 19 |
| Target Price | ★ $305.73 | $84.27 |
| AVG Volume (30 Days) | 698.1K | ★ 2.2M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 85.32 | 80.32 |
| EPS | ★ 8.48 | N/A |
| Revenue | ★ $13,008,900,000.00 | $4,144,000.00 |
| Revenue This Year | $8.00 | $15.18 |
| Revenue Next Year | $4.94 | $12.46 |
| P/E Ratio | $33.23 | ★ N/A |
| Revenue Growth | ★ 6.97 | N/A |
| 52 Week Low | $209.38 | $38.88 |
| 52 Week High | $293.72 | $103.87 |
Technical Indicators
Market Signals| Indicator | LH | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 67.49 |
| Support Level | $260.57 | $103.21 |
| Resistance Level | $292.02 | $103.42 |
| Average True Range (ATR) | 7.63 | 0.34 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 69.38 | 67.53 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.